Mersana Therapeutics

MRSN

Valor de mercado US$ 145 mi

MILWAUKEE , Dec. 16, 2025 /PRNewswire/ -- The Ademi Firm continues to investigate Mersana (NASDAQ: MRSN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Day One Biopharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

NEW YORK and NEW ORLEANS , Dec. 12, 2025 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Mersana Therapeutics, Inc. (NasdaqGS: MRSN) to Day One Biopharmaceuticals, Inc. Under the terms of the proposed transaction, shareholders of Mersana will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive certain potential milestone payments.

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $1.51 per share versus the Zacks Consensus Estimate of a loss of $1.44. This compares to a loss of $2.25 per share a year ago.

Mersana Therapeutics, Inc. ( MRSN ) M&A Call November 13, 2025 8:00 AM EST Company Participants Joey Perrone - Senior Vice President of Finance & Investor Relations Jeremy Bender - CEO, President & Director Michael Vasconcelles - Head of Research & Development Charles York - COO & CFO Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Alec Stranahan - BofA Securities, Research Division Kelsey Goodwin - Piper Sandler & Co., Research Division Ami Fadia - Needham & Company, LLC, Research Division Presentation Operator Hello, ladies and gentlemen, and welcome to the conference call and live webcast Day One Biopharmaceuticals to acquire Mersana Therapeutics. [Operator Instructions] Please be advised that this conference call is being recorded.

MILWAUKEE , Nov. 13, 2025 /PRNewswire/ -- The Ademi Firm is investigating Mersana (NASDAQ: MRSN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Day One Biopharmaceuticals. Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995.

Day One Biopharmaceuticals (NASDAQ: DAWN) on Thursday agreed to acquire Mersana Therapeutics Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers.

Shares of Mersana Therapeutics catapulted early Thursday after Day One Biopharmaceuticals agreed to buy it for up to $285 million.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mersana Therapeutics, Inc. (NASDAQ: MRSN) to Day One Biopharmaceuticals, Inc. is fair to Mersana shareholders. Under the terms of the proposed transaction, Mersana shareholders will receive $25.00 per share in cash plus one non-tradable contingent value right (CVR) per share to receive certain potential milestone payments of up to $30.25 per CVR in cash, for total consideration of up t.

Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 million